Form 4: STAAR Surgical CFO Deborah Andrews Awarded Significant RSU Grant

STAAR Surgical Company's new Chief Financial Officer, Deborah J. Andrews, was granted 41,867 Restricted Stock Units (RSUs) on June 25, 2025, as part of her compensation.

Summary

• Deborah J. Andrews, the Chief Financial Officer (CFO) of STAAR SURGICAL CO (STAA), was the reporting person for this transaction.
• On June 25, 2025, Ms. Andrews was awarded 41,867 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of STAAR Surgical's common stock upon vesting.
• The RSUs will vest in three equal installments: 1/3 of the shares on June 25, 2026, another 1/3 on June 25, 2027, and the final 1/3 on June 25, 2028.
• This RSU grant is directly connected to Ms. Andrews' appointment as Chief Financial Officer.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to the new CFO is a positive step for corporate governance and executive alignment, as it ties the executive's compensation to the long-term performance of the company. This is a standard and expected practice for executive appointments, reflecting a stable and structured approach to leadership incentives.

Positives

• The grant of 41,867 Restricted Stock Units (RSUs) to the new CFO aligns her long-term financial interests with the company's performance and shareholder value.
• The RSU award is a standard component of executive compensation, indicating a structured approach to incentivizing key leadership.

Future Outlook

The vesting schedule for the Restricted Stock Units extends to June 25, 2028, indicating a long-term incentive structure designed to retain and motivate the Chief Financial Officer over several years.

Management Comments

• "This Form 4 reflects the RSUs granted to Ms. Andrews in connection with her appointment as Chief Financial Officer on June 25, 2025."

Industry Context

The grant of Restricted Stock Units (RSUs) is a prevalent practice in executive compensation across various industries, including the medical device sector where STAAR Surgical operates. This method is widely used to align executive incentives with long-term company performance and shareholder value, reflecting a standard approach to attracting and retaining senior talent.

Comparison to Industry Standards

• Form 4 filings primarily serve as a disclosure of insider transactions and do not typically provide the necessary data for direct comparisons to specific industry compensation benchmarks or competitor equity grants. This filing solely reports an individual's equity transaction as part of their compensation package.

Management Changes

Stakeholder Impact

• Shareholders: The RSU grant aligns the CFO's incentives with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: May signal stability and a clear compensation strategy for executive leadership within the company.

Next Steps

• Vesting of 1/3 of the awarded RSUs on June 25, 2026.
• Vesting of another 1/3 of the awarded RSUs on June 25, 2027.
• Vesting of the final 1/3 of the awarded RSUs on June 25, 2028.

Key Dates

Keywords

STAAR Surgical, STAA, Restricted Stock Units, RSU, CFO, Executive Compensation, Insider Transaction, Form 4, Equity Grant